About this episode

This episode discusses a study on the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fibrosis, revealing significant findings.

Covering a very interesting study this week, which investiaged the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fibrosis (specifically including 325 patients with autoimmune ILD). Would have been yet another ho hum trial if not for the big reveal... have a listen to find out! Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2503643

More episodes of The Evidence Based Rheumatology Podcast

• E134: Brepocitinib in Dermatomyositis (VALOR) · April 17, 2026 · 15 min
• E133: Obinutuzumab for SLE (ALLEGORY) · March 19, 2026 · 15 min
• E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE) · March 5, 2026 · 14 min
• E131: A Sham-Controlled Sham of a Trial: RESET-RA · January 21, 2026 · 15 min
• E130: Telitacicept for SLE · December 22, 2025 · 13 min
• E129: Long Term Routine Laboratory Monitoring in RA · December 4, 2025 · 15 min

Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.